ReviewCaspian journal of internal medicine2025
Effect of Fampridine on cognition in patients with multiple sclerosis (MS): a systematic review and meta-analysis.
Review in Caspian journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment (CI) is a disabling complication in patients with multiple sclerosis (MS). Fampridine is used to improve walking abilities in subjects with MS while it is also used for improving cognition, although the results are heterogeneous. Therefore, we aimed to conduct a systematic review and meta-analysis to investigate the effect of fampridine on cognition in patients with MS. Methods: We performed a comprehensive search in PubMed, EMBASE, Scopus, Web of Science, google scholar, and also gray including references of the references and conference abstracts on January 1 Results: We identified 4972 studies in the preliminary search. After deduplication, 2607 articles remained. Two researchers screened the title and the abstracts, removing 2590 studies. Finally, 15 studies remained for meta-analysis. The included studies were published between 2013 and 2021, and the most frequent country of origin was Denmark. The mean age of participants of the studies ranged between 39 and 53 years and the mean EDSS ranged between 4 and 5.8, respectively. The SMD (standardized mean difference) of Symbol Digit Modalities Test (SDMT) (after-before treatment) was 0.45(95%CI: 0.06-0.84) (I Conclusions: Fampridine has a significant role in decreasing cognitive impairments is MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.